FDA Clears Pathwork Diagnostics' Test for FFPE | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pathwork Diagnostics today said it has received clearance from the US Food and Drug Administration for its Tissue of Origin test for formalin-fixed paraffin embedded tissue.

The Pathwork Tissue of Origin test can now be broadly used on common clinical FFPE tumor specimens from both community and research hospitals, Pathwork Diagnostics said in a statement. The clearance also clears the way for additional FFPE-based cancer tests on its platform, the company added.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.